Table 1.
Serovar | Vaccine | Parent | Genotype | Developer | Stage | References |
---|---|---|---|---|---|---|
Typhi | CVD 906 | ISP1820 | ΔaroC ΔaroD |
CVD | Phase 1 | [75] |
CVD 908 | Ty2 | ΔaroC ΔaroD |
CVD | Phase 1 | [19, 20, 72–74] | |
CVD 906-htrA | ISP1820 | ΔaroC ΔaroD ΔhtrA |
CVD | Phase 1 | [20] | |
CVD 908-htrA | Ty2 | ΔaroC ΔaroD ΔhtrA |
CVD | Phase 1 and 2 | [20] | |
CVD 909 | Ty2 | ΔaroC ΔaroD Ptac-tviA |
CVD | Phase 1 | [78] | |
Typhella (M01ZH09) | Ty2 | ΔaroC ΔssaV |
Prokarium | Phase 1 and 2 | [79–81, 107–109] | |
χ3927 | Ty2 | Δcya Δcrp | Curtiss, R. 3rd | Phase 1 | [19] | |
Ty800 | Ty2 | ΔphoPQ | Celldex Therapeutics | Phase 1 and 2 | [82] | |
Paratyphi A | CVD 1902 | ATCC 9150 | ΔguaBA ΔclpX |
CVD | Phase 1 | ClinicalTrials.gov: NCT01129453 |
MGN10028 | MGN9772 | ΔphoPQ | Celldex Therapeutics | Pre-clinical | [83] | |
Paratyphi B | CVD 2005 | CMF 6999 | ΔguaBA ΔclpX |
CVD | Pre-clinical | Higginson E., unpublished data |
Typhimurium | CVD 1921 | I77 | ΔguaBA ΔclpP |
CVD | Pre-clinical | [49] |
CVD 1931 | D65 | ΔguaBA ΔclpX |
CVD | Pre-clinical | Tennant, S.M., unpublished data | |
Enteritidis | CVD 1941 | R11 | ΔguaBA ΔclpP |
CVD | Pre-clinical | [49] |
CVD 1944 | R11 | ΔguaBA ΔclpX |
CVD | Pre-clinical | Tennant, S.M., unpublished data | |
Paratyphi C (C1) | TBD | TBD | TBD | CVD | Pre-clinical | Fuche, F., unpublished data |
Newport (C2) | TBD | TBD | TBD | CVD | Pre-clinical | Fuche, F., unpublished data |
TBD, To be determined